BiotchPharma Rare diseases, by their nature, are rare and difficult to diagnose and identify the disease. Companies wishing to conduct clinical trials on orphan drugs are generally classified as II and III. They face problems in treating a sufficient number of patients for phase clinical studies. BiotchPharma focuses on rare diseases for patients who need unmet therapy. Sustainable access to innovative and developing treatments is the right of every patient. That's why we strive to provide innovative Orphan Drugs in development to BiotchPharma patients and doctors Biotchpharma on Turkey's pharmaceutical and genetic markets (especially oncology, hematology and rare diseases) serve. BiotchPharma consists of people with professional experience in different global companies in medical and genetics, sales and marketing, and reimbursement and registration (licensing) and post-trial access. With this knowledge and experience, we created BiotchPharma. Turkey is a big market with a population of 80 million and growing field of health is very ope info@biotchpharma.com Rare Disease in the Pharmaceutical Sector and Rare Diseases -Start up drug -Early Access Program (Early Access) Country Manager in the field of Hematology Oncology and Psychiatry and Breast Cancer Tests Start up and country management. Entering new markets like oncology, hematology, orphan diseases and psychiatry. Developing KOLs and Advisory Board in those new markets. Providing consultative, functional and operational support to for Expanded Access / Compassionate Use of investigational drugs. Management of the relations with MoH (Ministry of Health), SGK (Social Security Institution) and TEB (Turkish Pharmasists Association which is the only wholesaler in NPI) on behalf of the Company Specialties: Head of Market Access NPI (Named Patient Import) Compassionate Use Early Access Programmes Sales Marketing Key Account Management KOL management Public affairs management CRM info@biotchpharma.com